Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review
Abstract
:Simple Summary
Abstract
1. Introduction
2. Results
2.1. Sources of Bias
2.2. Brain
2.3. Head and Neck
2.4. Lung
2.5. Breast
2.6. Upper Gastrointestinal Tract
2.7. Liver, Gallbladder, Pancreas
2.8. Lower Gastrointestinal Tract
2.9. Prostate
2.10. Bone
3. Discussion
4. Methods
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Giammarile, F.; Castellucci, P.; Dierckx, R.; Estrada Lobato, E.; Farsad, M.; Hustinx, R.; Jalilian, A.; Pellet, O.; Rossi, S.; Paez, D. Non-FDG PET/CT in Diagnostic Oncology: A pictorial review. Eur. J. Hybrid Imaging 2019, 3, 20. [Google Scholar] [CrossRef] [Green Version]
- Hillner, B.E.; Siegel, B.A.; Liu, D.; Shields, A.F.; Gareen, I.F.; Hanna, L.; Stine, S.H.; Coleman, R.E. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: Initial results from the National Oncologic PET Registry. J. Clin. Oncol. 2008, 26, 2155–2161. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Evidence-Based Indications for the Use of PET-CT in the United Kingdom 2016 | The Royal College of Radiologists. Available online: https://www.rcr.ac.uk/publication/evidence-based-indications-use-pet-ct-united-kingdom-2016 (accessed on 8 July 2020).
- Loktev, A.; Lindner, T.; Mier, W.; Debus, J.; Altmann, A.; Jäger, D.; Giesel, F.; Kratochwil, C.; Barthe, P.; Roumestand, C.; et al. A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. J. Nucl. Med. 2018, 59, 1423–1429. [Google Scholar] [CrossRef] [PubMed]
- Poplawski, S.E.; Lai, J.H.; Li, Y.; Jin, Z.; Liu, Y.; Wu, W.; Wu, Y.; Zhou, Y.; Sudmeier, J.L.; Sanford, D.G.; et al. Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase. J. Med. Chem. 2013, 56, 3467–3477. [Google Scholar] [CrossRef] [Green Version]
- Jansen, K.; Heirbaut, L.; Cheng, J.D.; Joossens, J.; Ryabtsova, O.; Cos, P.; Maes, L.; Lambeir, A.-M.; De Meester, I.; Augustyns, K.; et al. Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold. ACS Med. Chem. Lett. 2013, 4, 491–496. [Google Scholar] [CrossRef]
- Lindner, T.; Loktev, A.; Altmann, A.; Giesel, F.; Kratochwil, C.; Debus, J.; Jäger, D.; Mier, W.; Haberkorn, U. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. J. Nucl. Med. 2018, 59, 1415–1422. [Google Scholar] [CrossRef] [Green Version]
- Syed, M.; Flechsig, P.; Liermann, J.; Windisch, P.; Haberkorn, U.; Debus, J.; Adeberg, S. Fibroblast Activation Protein (FAPI) Specific PET for Advanced Target Volume Delineation in Head and Neck Cancer. Int. J. Radiat. Oncol. Biol. Phys. 2019, 105, E383. [Google Scholar] [CrossRef]
- Afshar-Oromieh, A.; Avtzi, E.; Giesel, F.L.; Holland-Letz, T.; Linhart, H.G.; Eder, M.; Eisenhut, M.; Boxler, S.; Hadaschik, B.A.; Kratochwil, C.; et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2015, 42, 197–209. [Google Scholar] [CrossRef] [Green Version]
- Hellman, S.; Weichselbaum, R.R. Oligometastases. J. Clin. Oncol. 1995, 13, 8–10. [Google Scholar] [CrossRef]
- Röhrich, M.; Loi, L.; Floca, R.; Haberkorn, U.; Paech, D. Dataset of voxelwise correlated signal values of ADC, rCBV and FAP-specific PET of 13 Glioblastoma patients. Data Brief 2020, 31, 105712. [Google Scholar] [CrossRef]
- Chen, H.; Pang, Y.; Wu, J.; Zhao, L.; Hao, B.; Wu, J.; Wei, J.; Wu, S.; Zhao, L.; Luo, Z.; et al. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 1820–1832, Reply in 2020, 47, 2080–2082. [Google Scholar] [CrossRef] [PubMed]
- Luo, Y.; Pan, Q.; Zhang, W. IgG4-related disease revealed by 68Ga-FAPI and 18F-FDG PET/CT. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 2625–2626. [Google Scholar] [CrossRef] [PubMed]
- Luo, Y.; Pan, Q.; Yang, H.; Peng, L.; Zhang, W.; Li, F. Fibroblast activation protein targeted PET/CT with 68Ga-FAPI for imaging IgG4-related disease: Comparison to 18F-FDG PET/CT. J. Nucl. Med. 2020. [Google Scholar] [CrossRef] [PubMed]
- Pan, Q.; Luo, Y.; Zhang, W. Recurrent Immunoglobulin G4-Related Disease Shown on 18F-FDG and 68Ga-FAPI PET/CT. Clin. Nucl. Med. 2020, 45, 312–313. [Google Scholar] [CrossRef]
- Totzeck, M.; Siebermair, J.; Rassaf, T.; Rischpler, C. Cardiac fibroblast activation detected by positron emission tomography/computed tomography as a possible sign of cardiotoxicity. Eur. Heart J. 2020, 41, 1060. [Google Scholar] [CrossRef]
- Hao, B.; Wu, X.; Pang, Y.; Sun, L.; Wu, H.; Huang, W.; Chen, H. [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of tuberculous lesions. Eur. J. Nucl. Med. Mol. Imaging 2020. [Google Scholar] [CrossRef]
- Hintz, H.M.; Gallant, J.P.; Vander Griend, D.J.; Coleman, I.; Nelson, P.S.; LeBeau, A.M. Imaging Fibroblast Activation Protein Alpha improves diagnosis of metastatic Prostate Cancer with Positron Emission Tomography. Clin. Cancer Res. 2020. [Google Scholar] [CrossRef]
- Zheng, J.; Yao, S. [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with hepatic cancer. Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 2078–2079. [Google Scholar] [CrossRef]
- Laffon, E.; Marthan, R. Reversibility of 68Ga-FAPI-2 Trapping Might Prove an Asset for PET Quantitative Imaging. J. Nucl. Med. 2020, 61, 620. [Google Scholar] [CrossRef]
- Zhao, L.; Gu, J.; Fu, K.; Lin, Q.; Chen, H. 68Ga-FAPI PET/CT in Assessment of Liver Nodules in a Cirrhotic Patient. Clin. Nucl. Med. 2020, 45, e430–e432. [Google Scholar] [CrossRef]
- Wang, G.; Jin, X.; Zhu, H.; Wang, S.; Ding, J.; Zhang, Y.; Yang, Z.; Wang, X. 68Ga-NOTA-FAPI-04 PET/CT in a patient with primary gastric diffuse large B cell lymphoma: Comparisons with [18F] FDG PET/CT. Eur. J. Nucl. Med. Mol. Imaging 2020. [Google Scholar] [CrossRef] [PubMed]
- Windisch, P.; Röhrich, M.; Regnery, S.; Tonndorf-Martini, E.; Held, T.; Lang, K.; Bernhardt, D.; Rieken, S.; Giesel, F.; Haberkorn, U.; et al. Fibroblast Activation Protein (FAP) specific PET for advanced target volume delineation in glioblastoma. Radiother. Oncol. 2020, 150, 159–163. [Google Scholar] [CrossRef] [PubMed]
- Giesel, F.; Adeberg, S.; Syed, M.; Lindner, T.; Jimenez, L.D.; Mavriopoulou, E.; Staudinger, F.; Tonndorf-Martini, E.; Regnery, S.; Rieken, S.; et al. FAPI-74 PET/CT Using Either 18F-AlF or Cold-kit 68Ga-labeling: Biodistribution, Radiation Dosimetry and Tumor Delineation in Lung Cancer Patients. J. Nucl. Med. 2020. [Google Scholar] [CrossRef] [PubMed]
- Chen, H.; Zhao, L.; Ruan, D.; Pang, Y.; Hao, B.; Dai, Y.; Wu, X.; Guo, W.; Fan, C.; Wu, J.; et al. Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings. Eur. J. Nucl. Med. Mol. Imaging 2020. [Google Scholar] [CrossRef] [PubMed]
- Shi, X.; Xing, H.; Yang, X.; Li, F.; Yao, S.; Zhang, H.; Zhao, H.; Hacker, M.; Huo, L.; Li, X. Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET/CT: A pilot study in patients with suspected hepatic nodules. Eur. J. Nucl. Med. Mol. Imaging 2020. [Google Scholar] [CrossRef]
- Pang, Y.; Huang, H.; Fu, L.; Zhao, L.; Chen, H. 68Ga-FAPI PET/CT Detects Gastric Signet-Ring Cell Carcinoma in a Patient Previously Treated for Prostate Cancer. Clin. Nucl. Med. 2020, 45, 632–635. [Google Scholar] [CrossRef]
- Pang, Y.; Hao, B.; Shang, Q.; Sun, L.; Chen, H. Comparison of 68Ga-FAPI and 18F-FDG PET/CT in a Patient With Cholangiocellular Carcinoma: A Case Report. Clin. Nucl. Med. 2020, 45, 566–567. [Google Scholar] [CrossRef]
- Chen, H.; Zhao, L.; Ruan, D.; Sun, L.; Lin, Q. 68Ga-FAPI PET/CT Improves Therapeutic Strategy by Detecting a Second Primary Malignancy in a Patient With Rectal Cancer. Clin. Nucl. Med. 2020, 45, 468–470. [Google Scholar] [CrossRef]
- Koerber, S.A.; Staudinger, F.; Kratochwil, C.; Adeberg, S.; Haefner, M.F.; Ungerechts, G.; Rathke, H.; Winter, E.; Lindner, T.; Syed, M.; et al. The role of FAPI-PET/CT for patients with malignancies of the lower gastrointestinal tract—First clinical experience. J. Nucl. Med. 2020. [Google Scholar] [CrossRef]
- Luo, Y.; Pan, Q.; Zhang, W.; Li, F. Intense FAPI Uptake in Inflammation May Mask the Tumor Activity of Pancreatic Cancer in 68Ga-FAPI PET/CT. Clin. Nucl. Med. 2020, 45, 310–311. [Google Scholar] [CrossRef]
- Meyer, C.; Dahlbom, M.; Lindner, T.; Vauclin, S.; Mona, C.; Slavik, R.; Czernin, J.; Haberkorn, U.; Calais, J. Radiation dosimetry and biodistribution of 68Ga-FAPI-46 PET imaging in cancer patients. J. Nucl. Med. 2020, 61, 1171–1177. [Google Scholar] [CrossRef] [PubMed]
- Khreish, F.; Rosar, F.; Kratochwil, C.; Giesel, F.L.; Haberkorn, U.; Ezziddin, S. Positive FAPI-PET/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative/FDG-positive disease. Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 2040–2041. [Google Scholar] [CrossRef] [PubMed]
- Röhrich, M.; Loktev, A.; Wefers, A.K.; Altmann, A.; Paech, D.; Adeberg, S.; Windisch, P.; Hielscher, T.; Flechsig, P.; Floca, R.; et al. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 2569–2580. [Google Scholar] [CrossRef] [PubMed]
- Röhrich, M.; Floca, R.; Loi, L.; Adeberg, S.; Windisch, P.; Giesel, F.L.; Kratochwil, C.; Flechsig, P.; Rathke, H.; Lindner, T.; et al. FAP-specific PET signaling shows a moderately positive correlation with relative CBV and no correlation with ADC in 13 IDH wildtype glioblastomas. Eur. J. Radiol. 2020, 127, 109021. [Google Scholar] [CrossRef]
- Kratochwil, C.; Flechsig, P.; Lindner, T.; Abderrahim, L.; Altmann, A.; Mier, W.; Adeberg, S.; Rathke, H.; Röhrich, M.; Winter, H.; et al. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J. Nucl. Med. 2019, 60, 801–805. [Google Scholar] [CrossRef] [Green Version]
- Giesel, F.; Kratochwil, C.; Lindner, T.; Marschalek, M.; Loktev, A.; Lehnert, W.; Debus, J.; Jäger, D.; Flechsig, P.; Altmann, A.; et al. FAPI-PET/CT: Biodistribution and preliminary dosimetry estimate of two DOTA-containing FAP-targeting agents in patients with various cancers. J. Nucl. Med. 2019, 60, 386–392. [Google Scholar] [CrossRef] [Green Version]
- Giesel, F.L.; Heussel, C.P.; Lindner, T.; Röhrich, M.; Rathke, H.; Kauczor, H.-U.; Debus, J.; Haberkorn, U.; Kratochwil, C. FAPI-PET/CT improves staging in a lung cancer patient with cerebral metastasis. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 1754–1755. [Google Scholar] [CrossRef]
- Donche, S.; Verhoeven, J.; Descamps, B.; Bolcaen, J.; Deblaere, K.; Boterberg, T.; Van den Broecke, C.; Vanhove, C.; Goethals, I. The Path Toward PET-Guided Radiation Therapy for Glioblastoma in Laboratory Animals: A Mini Review. Front. Med. 2019, 6, 5. [Google Scholar] [CrossRef] [Green Version]
- Law, I.; Albert, N.L.; Arbizu, J.; Boellaard, R.; Drzezga, A.; Galldiks, N.; la Fougère, C.; Langen, K.-J.; Lopci, E.; Lowe, V.; et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F] FDG: Version 1.0. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 540–557. [Google Scholar] [CrossRef] [Green Version]
- Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009, 6, e1000097. [Google Scholar] [CrossRef] [Green Version]
Title | Author | Year | Tumor (Patients) | Tracer (Patients) | Key Findings | COI | Funding |
---|---|---|---|---|---|---|---|
68Ga-NOTA-FAPI-04 PET/CT in a patient with primary gastric diffuse large B cell lymphoma: comparisons with [(18)F] FDG PET/CT | Wang et al. [22] | 2020 |
|
|
| none | Beijing Municipal Science & Technology Commission |
Fibroblast Activation Protein (FAP) specific PET for advanced target volume delineation in Glioblastoma | Windisch et al. [23] * same patient collective as Röhrich et al. | 2020 |
|
|
| Patent application | none |
FAPI-74 PET/CT Using Either 18F-AlF or Cold-kit 68Ga-labeling: Biodistribution, Radiation Dosimetry and Tumor Delineation in Lung Cancer Patients | Giesel, Adeberg et al. [24] | 2020 |
|
|
| Patent application, Shares in Consultancy group | none |
Usefulness of [68Ga] Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F] FDG PET/CT findings | Chen et al. [25] | 2020 |
|
|
| none | National Natural Science Foundation of China |
Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET/CT: a pilot study in patients with suspected hepatic nodules. | Shi et al. [26] | 2020 |
|
|
| none | National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, CAMS Innovation Fund for Medical Sciences |
68Ga-FAPI PET/CT Detects Gastric Signet-Ring Cell Carcinoma in a Patient Previously Treated for Prostate Cancer | Pang et al. [27] | 2020 |
|
|
| none | none |
Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers | Syed et al. [8] | 2020 |
|
|
| Patent application, Shares in Consultancy group | Open Access funding provided by Projekt DEAL |
Comparison of 68Ga-FAPI and 18F-FDG PET/CT in a Patient With Cholangiocellular Carcinoma: A Case Report | Pang et al. [28] | 2020 |
|
|
| none | none |
FAP-specific PET signaling shows a moderately positive correlation with relative CBV and no correlation with ADC in 13 IDH wildtype glioblastomas | Röhrich et al. [11] * same patient collective as Windisch et al. | 2020 |
|
|
| Patent application | Federal Ministry of Education and Research |
Comparison of [68Ga] Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer | Chen et al. [12] | 2020 |
|
|
| none | National Natural Science Foundation of China |
68Ga-FAPI PET/CT Improves Therapeutic Strategy by Detecting a Second Primary Malignancy in a Patient With Rectal Cancer. | Chen et al. [29] | 2020 |
|
|
| none | none |
The role of FAPI-PET/CT for patients with malignancies of the lower gastrointestinal tract - first clinical experience | Koerber et al. [30] | 2020 |
|
|
| Patent application | none |
Intense FAPI Uptake in Inflammation May Mask the Tumor Activity of Pancreatic Cancer in 68Ga-FAPI PET/CT | Luo et al. [31] | 2020 |
|
|
| none | CAMS Initiative for Innovative Medicine |
Radiation dosimetry and biodistribution of 68Ga-FAPI-46 PET imaging in cancer patients | Meyer et al. [32] | 2019 |
|
|
| Patent application | none |
Positive FAPI-PET/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative/FDG-positive disease | Khreish et al. [33] | 2019 |
|
|
| Patent application | none |
IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT | Röhrich et al. [34] * same patient collective as Windisch et al. | 2019 |
|
|
| none | Federal Ministry of Education and Research |
FAPI-PET/CT improves staging in a lung cancer patient with cerebral metastasis | Giesel et al. [35] | 2019 |
|
|
| Patent application | |
68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. | Kratochwil et al. [36] | 2019 |
|
|
| Patent application | none |
68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers | Giesel et al. [37] | 2018 |
|
|
| Patent application | none |
Title | Estimated Enrollment | Estimated Study Completion Date | Tumors | Tracer | Location | Key Interventions |
---|---|---|---|---|---|---|
The Role of 68Ga-FAPI-04 PET/CT in Gastric and Pancreatic Cancers | 25 patients | 06/2021 |
| 68Ga-FAPI-04 | Tel-Aviv Sourasky Medical Center |
|
68Ga-FAPI PET Imaging in Malignancy | 30 patients | 12/2021 |
| 68Ga-FAPI (not specified) | Stanford University Hospitals and Clinics |
|
Comparison of FDG and FAPI in Patients With Various Types of Cancer | 600 patients | 12/2021 |
| 68Ga-FAPI-04 | The First Affiliated Hospital of Xiamen University |
|
PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Prostate Cancer: A Prospective Exploratory Biodistribution Study With Histopathology Validation | 30 patients | 07/2023 |
| 68Ga-FAPI-46 | UCLA/Jonsson Comprehensive Cancer Center |
|
PET Biodistribution Study of 68Ga-PSMA-11 and 68Ga-FAPI-46 in Patients With Non-Prostate Cancers: An Exploratory Biodistribution Study With Histopathology Validation | 30 patients | 10/2021 |
| 68Ga-FAPI-46 | UCLA/Jonsson Comprehensive Cancer Center |
|
PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Different Malignancies: An Exploratory Biodistribution Study With Histopathology Validation | 30 patients | 07/2024 |
| 68Ga-FAPI-46 | UCLA/Jonsson Comprehensive Cancer Center |
|
Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma | 200 patients | 12/2020 |
| 68Ga-FAPI-0418F-FAPI-04 | Peking University Cancer Hospital |
|
PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Sarcoma: An Exploratory Biodistribution Study With Histopathology Validation | 30 patients | 07/2024 |
| 68Ga-FAPI-46 | UCLA/Jonsson Comprehensive Cancer Center |
|
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Windisch, P.; Zwahlen, D.R.; Koerber, S.A.; Giesel, F.L.; Debus, J.; Haberkorn, U.; Adeberg, S. Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review. Cancers 2020, 12, 2629. https://doi.org/10.3390/cancers12092629
Windisch P, Zwahlen DR, Koerber SA, Giesel FL, Debus J, Haberkorn U, Adeberg S. Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review. Cancers. 2020; 12(9):2629. https://doi.org/10.3390/cancers12092629
Chicago/Turabian StyleWindisch, Paul, Daniel R. Zwahlen, Stefan A. Koerber, Frederik L. Giesel, Jürgen Debus, Uwe Haberkorn, and Sebastian Adeberg. 2020. "Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review" Cancers 12, no. 9: 2629. https://doi.org/10.3390/cancers12092629